AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9124833
Drug: Dapsone 100
RxNorm normalized name: dapsone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 100 mg biweekly with Rifampin
Trial: 9124833
Drug: Dapsone 100
RxNorm normalized name: dapsone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 100 mg biweekly without Rifampin
Trial: 9124833
Drug: Dapsone with
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone with high bilirubin levels (> 1.2 mg/dl)
Trial: 9124833
Drug: Dapsone with
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone with normal bilirubin levels (0.7 mg/dl)
Trial: 1559334
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of contraceptive tablet (0.25 mg LNG, 0.05 mg ethinylestradiol)
Trial: 1559334
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of contraceptive tablet (0.25 mg LNG, 0.05 mg ethinylestradiol)
Trial: 1559334
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (oral and vaginal)
Trial: 30345939
Drug: Nutrition education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition education curriculum (implemented twice per week for 6 weeks)
Trial: 29325289
Drug: Entecavir 0.5
RxNorm normalized name: entecavir 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.5 mg/d for 208 weeks
Trial: 29325289
Drug: Telbivudine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 0.6 g/d for 208 weeks
Trial: 23490224
Drug: BEA2180 (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEA2180 (50, 100 or 200 μg)
Trial: 23490224
Drug: Tiotropium (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (5 μg)
Trial: 23490224
Drug: BEA2180 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEA2180 (200 μg)
Trial: 23490224
Drug: BEA2180 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEA2180 (50 and 200 μg)
Trial: 9146850
Drug: Prednisolone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (1.5 mg kg‐1)
Trial: 7964943
Drug: UFT 350
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 350 mg/m2/d plus oral leucovorin 150 mg/d
Trial: 7964943
Drug: UFT 300
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 300 mg/m2/d plus oral leucovorin 150 mg/d
Trial: 3596338
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg at 2300 h
Trial: 3596338
Drug: Cimetidine 1200
RxNorm normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1200 mg at 2300 h
Trial: 3596338
Drug: Cimetidine 1600
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 1600 mg at 2300 h
Trial: 3596338
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg bd (0800 h and 2300 h)
Trial: 3596338
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg at 1800 h
Trial: 3596338
Drug: Cimetidine 1600
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 1600 mg at 1800 h
Trial: 3596338
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg at 1800 h
Trial: 29212965
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day pitavastatin plus 10 mg/day ezetimibe
Trial: 27755389
Drug: Sequential nephron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential nephron blockade
Trial: 27755389
Drug: Sequential renin-angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential renin-angiotensin system blockade
Trial: 14600517
Drug: High-dose multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose multiple micronutrient supplementation
Trial: 10825334
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg IV (Group O4)
Trial: 10825334
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg IV (Group O8)
Trial: 31892352
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion at a rate of 0, 1, 2, 3, 5, or 8 IU h(‐ 1) for a total of 1 h
Trial: 31892352
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion at increasing rates
Trial: 31892352
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 IU h(‐ 1) infusion)
Trial: 24929133
Drug: Multi-component integrated
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component integrated control strategy including bovine vaccination using a heterologous 'prime-boost' delivery platform based on the SjCTPI vaccine.
Trial: 24929133
Drug: Mass human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mass human chemotherapy and mollusciciding as part of the integrated strategy.
Trial: 9491040
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl, 15 to 20 microgram/kg
Trial: 30180236
Drug: L-arginine mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine mouthwash
Trial: 30180236
Drug: D-panthenol gel
RxNorm normalized name: D-PANTHENOL
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-panthenol gel
Trial: 23579036
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel
Trial: 30180236
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of corn oil gel (placebo)
Trial: 30180236
Drug: Triester glycerol
RxNorm normalized name: Triester Glycerol Oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triester glycerol oxide gel
Trial: 24842806
Drug: Transient ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transient ovarian suspension
Trial: 16060401
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg gabapentin (100 mg, twice daily)
Trial: 16060401
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg gabapentin (100 mg, four times daily)
Trial: 16060401
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg gabapentin (200 mg, three times daily)
Trial: 12192247
Drug: anti‐BLyS monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti‐BLyS monoclonal antibody
Trial: 12192247
Drug: anti‐CD40L monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti‐CD40L monoclonal antibody
Trial: 7477802
Drug: Combined cognitive-behavioral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive-behavioral, nutritional and antidepressant therapy (5 with amineptine and 10 with fluvoxamine)
Trial: 7036932
Drug: Clofibrate (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibrate (single oral dose)
Trial: 31480678
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group treatment (CBT) with development-specific topics for adolescents and young adults (YOUTH)
Trial: 25677397
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with fluoxetine 20-40 mg/day plus interpersonal psychotherapy adapted to BPD (IPT-BPD) for 32 weeks
Trial: 25677397
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with fluoxetine 20-40 mg/day plus IPT-BPD
Trial: 21679182
Drug: High PCO2
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High PCO2 solution
Trial: 21679182
Drug: 0.1 N
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 N HCl solution (acid perfusion)
Trial: 19358119
Drug: Postoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative oral and nasal steroid therapy
Trial: 17953808
Drug: Vitamin B12,
RxNorm normalized name: Vitamin B12, 50 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12, folic acid, L-carnitine, and betaine supplementation
Trial: 2678805
Drug: 0‐(beta‐Hydroxylethyl)‐rutoside (HR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 600 mg
Trial: 2678805
Drug: 0‐(beta‐Hydroxylethyl)‐rutoside (HR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 900 mg
Trial: 2678805
Drug: 0‐(beta‐Hydroxylethyl)‐rutoside (HR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 1200 mg
Trial: 2678805
Drug: 0‐(beta‐Hydroxylethyl)‐rutoside (HR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 1500 mg
Trial: 1170119
Drug: Insulin 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 0.05 μ/kg body weight injected intravenously at 8 a.m.
Trial: 1170119
Drug: Insulin 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 0.05 μ/kg body weight injected intravenously at 5 p.m.
Trial: 1170119
Drug: Insulin injection
RxNorm normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection in the afternoon vs morning
Trial: 1170119
Drug: Caloric change
RxNorm normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric change in plasma after insulin injection
Trial: 1170119
Drug: Plasma growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma growth hormone response
Trial: 28331291
Drug: DA-8031 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-8031 at doses of 5, 10, 20, 40, 60, 80, or 120 mg
Trial: 28331291
Drug: DA-8031 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-8031 (80 mg or less)
Trial: 26385201
Drug: Cannabis (12.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis (12.5% tetrahydrocannabinol), median daily dose of 2.5 g/d
Trial: 22046230
Drug: Informed consent
RxNorm normalized name: Consensi
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Informed consent comprehension quiz administered at enrollment and during follow-up
Trial: 11053903
Drug: Trovafloxacin 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trovafloxacin 300 mg/24 h
Trial: 11053903
Drug: Ciprofloxacin 400
RxNorm normalized name: ciprofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400 mg/12 h
Trial: 11053903
Drug: Trovafloxacin 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trovafloxacin 300 mg/24 h plus cefepime 2 g/12 h
Trial: 11053903
Drug: Ciprofloxacin 400
RxNorm normalized name: ciprofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400 mg/12 h plus cefepime 2 g/12 h
Trial: 11053903
Drug: Combination regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimens (both)
Trial: 25907157
Drug: Maintenance antidepressants
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance antidepressants
Trial: 26068110
Drug: Exogenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exogenous insulin delivery
Trial: 10852359
Drug: Expressed desire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expressed desire for treatment
Trial: 10852359
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or more previous treatment admissions
Trial: 10852359
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of injection
Trial: 10852359
Drug: Giving money
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giving money or drugs for sex
Trial: 10852359
Drug: Level of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level of injection-related risk for HIV infection
Trial: 6383269
Drug: LYCD ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYCD ointment
Trial: 6383269
Drug: Ointment base
RxNorm normalized name: Ointment base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment base (Control)
Trial: 2880362
Drug: Perphenazine (20.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (20.5 mg/day)
Trial: 2880362
Drug: Haloperidol (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5.5 mg/day)
Trial: 2880362
Drug: Haloperidol (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (11 mg/day) + Biperiden (7 mg/day)
Trial: 2880362
Drug: Chlorprothixene (142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorprothixene (142 mg/day)
Trial: 18410803
Drug: Day cream
RxNorm normalized name: Gyne-Lotrimin 3 Day Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day cream with photostable combination of UVB and UVA filters
Trial: 10894871
Drug: Cyclophosphamide, methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, methotrexate, and fluorouracil (CMF) - 6 cycles; Cyclophosphamide 100 mg/m² orally days 1 to 14, Methotrexate 40 mg/m² IV days 1 and 8, Fluorouracil 600 mg/m² IV days 1 and 8
Trial: 10894871
Drug: Tamoxifen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen plus ovarian suppression (5 years of tamoxifen 30 mg/d, plus surgical oophorectomy, ovarian irradiation, or monthly goserelin 3.6 mg injections)
Trial: 8507018
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg nalbuphine
Trial: 7760093
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg propofol
Trial: 29655626
Drug: 3+1 (PCV7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3+1 (PCV7 booster after 3 priming doses)
Trial: 29655626
Drug: 3+0 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3+0 (3 doses of PCV7)
Trial: 29655626
Drug: 0+2 (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0+2 (control group, 12 and 18 months doses)
Trial: 25518508
Drug: Cytoflavin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (2 tablets b.i.d. on days 1 to 25) during standard basic therapy
Trial: 25518508
Drug: Standard basic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard basic therapy only
Trial: 20136785
Drug: Alemtuzumab (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab (single dose)
Trial: 15805318
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment followed by 5 minutes of 4% liposomal lidocaine cream
Trial: 11420886
Drug: ARTEM (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARTEM (300 mg)
Trial: 11420886
Drug: MQ (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MQ (750 mg)
Trial: 11420886
Drug: QN (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QN (600 mg)
Trial: 11420886
Drug: PQ (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PQ (45 mg)
Trial: 11420886
Drug: ARTEM (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARTEM (300 mg) + MQ (750 mg)
Trial: 11420886
Drug: ARTEM (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARTEM (300 mg) + QN (600 mg)
Trial: 11420886
Drug: ARTEM (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARTEM (300 mg) + PQ (45 mg)
Trial: 25672892
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D (1,000 mg calcium carbonate and 400 IU vitamin D3 per day)
Trial: 18231120
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of vitamin D drops containing 10 microg (400 IU) of ergocalciferol (vitamin D(2)) with information brochure
Trial: 18231120
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of vitamin D drops
Trial: 9399276
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate (rapid infusion)
Trial: 9399276
Drug: Infusion rate
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate (two rates studied in vivo)
Trial: 9399276
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion rate
Trial: 3115780
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg day‐1 of flecainide
Trial: 3115780
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg day‐1 of flecainide
Trial: 28623471
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine (1.5 mg kg−1 bolus then 1 mg kg−1 per hour)
Trial: 28232170
Drug: Ketamine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (target plasma level=100ng/ml)
Trial: 21328373
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (ETV or ADV)
Trial: 19548415
Drug: Optosil/Xantopren L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optosil/Xantopren L (Heraeus Kulzer)
Trial: 15169686
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean modal dose= 9.63 mg/day)
Trial: 15169686
Drug: Haloperidol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (mean modal dose=4.60 mg/day)
Trial: 9845936
Drug: Naltrexone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone administered prophylactically for 6 months or longer
Trial: 8919632
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg by single daily administration (Group A)
Trial: 8919632
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg for the first 3 days, then 5 mg thereafter (Group B)
Trial: 2184654
Drug: Indapamide in
RxNorm normalized name: Product containing indapamide in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide in combination with captopril (group II)
Trial: 2184654
Drug: Indapamide in
RxNorm normalized name: Product containing indapamide in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide in combination with propranolol (group III)
Trial: 6110803
Drug: Camazepam 40
RxNorm normalized name: halazepam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camazepam 40 mg
Trial: 16921035
Drug: VACA-IE (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VACA-IE (chemotherapy with doxorubicin, vincristine, cyclophosphamide, dactinomycin alternating with ifosfamide and etoposide)
Trial: 16921035
Drug: VACA (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VACA (chemotherapy with doxorubicin, vincristine, cyclophosphamide, dactinomycin)
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 10 mg/kg body weight/day for 20 days
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 10 mg/kg body weight/day for 40 days
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 15 mg/kg body weight/day for 20 days
Trial: 2840172
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 15 mg/kg body weight/day for 40 days